In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation.

We'll be discussing how antibody drug conjugates (ADCs) are transforming cancer care and with AI-powered pathology, doctors can now measure her HER2 more precisely to match patients with the best treatments.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Dr. Rob Monroe, Vice President and Chief Scientific Officer, Oncology, Danaher Corporation; Chief Medical Officer, Leica Biosystems

Jennifer Faikish, Vice President and Franchise Head, Oncology, Danaher Corporation

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

BioSpace

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment